NCT03879655

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

A Phase 2B/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Mandos LLC · Industry
• Sex: All
• Age: 4 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, multinational, open-label study of VTS-270 to evaluate the long-term safety and tolerability of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 (Parts A/B \[NCT02534844\] and Part C \[NCT04958642\]) with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease.

Detailed description

Non-clinical studies and a Phase 1 clinical trial suggest that intrathecal (IT) administration of VTS-270 in participants with neurologic manifestations of NPC1 disease has the potential to slow the rate of progression of their neurologic disease. NPC1 disease is a rare, neurodegenerative, inherited, autosomal recessive lysosomal lipid storage disorder primarily in children and teenagers. The disease is characterized by the inability to properly metabolize cholesterol and other lipids within the cell due to mutations in the NPC1 gene causing unesterified cholesterol to accumulate in the brain, liver and spleen. Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via lumbar puncture (LP) infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the participant, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.

Conditions

• Niemann-Pick Disease, Type C

Interventions

Type	Name	Description
DRUG	VTS-270	Administered IT via LP infusion of VTS-270

Timeline

• Start date: 2019-12-02
• Primary completion: 2021-10-18
• Completion: 2021-10-18
• First posted: 2019-03-19
• Last updated: 2023-12-26
• Results posted: 2023-12-26

Locations

1 site across 1 country: Costa Rica

Regulatory

• FDA-regulated drug study